.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) significantly impact the health of older adults globally. Researchers recently presented promising results for VXB-241, a bivalent RSV hMPV vaccine candidate, in a Phase 1 clinical trial. This study evaluates the safety and immunogenicity of this unadjuvanted liquid formulation designed to simplify vaccination schedules.
The ongoing randomised trial involved older adults aged 60 to 83 years. Participants received varying doses of VXB-241, ranging from 60 μg to 480 μg. Investigators compared these groups against a placebo and the licensed AS01-adjuvanted RSV vaccine. Specifically, the interim analysis focused on safety and antibody responses one month after injection.
Data showed that VXB-241 induced robust neutralising antibody titres against RSV-A, RSV-B, hMPV-A, and hMPV-B. Furthermore, the 240 μg dose level yielded geometric mean fold increases that compared favourably with the active control. For instance, RSV-A and RSV-B responses were at least as high as those seen with the licensed adjuvanted vaccine. Additionally, VXB-241 elicited strong responses against hMPV, whereas the active control showed negligible effects against this virus.
Regarding safety, the candidate vaccine displayed a clinically acceptable profile. While solicited adverse events occurred more frequently in the vaccine groups than in the placebo group, most reactions were mild and transient. Moreover, no safety signals emerged during this interim analysis. Consequently, these findings support the continued clinical development of VXB-241 as a potential tool for protecting older populations.
VXB-241 is a bivalent vaccine candidate that targets both RSV and hMPV. It utilizes a recombinant glycoprotein F-molecular clamp technology to stabilise viral antigens in their pre-fusion state, which enhances the immune response.
Yes, the 1-month interim analysis of the Phase 1 trial reported a clinically acceptable safety and reactogenicity profile. Most adverse events were mild and no significant safety signals emerged among the older adult participants during the study period.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition or vaccination. Refer to the latest local and national guidelines for clinical practice.
References
Della Cioppa G et al. Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial. Vaccine. 2026 Jun 01. doi: undefined. PMID: 42224773.
ClinicalTrials.gov. A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults. NCT06556147.
Vicebio Ltd. Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine. PR Newswire. November 21, 2024.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
VXB-241, a bivalent RSV and hMPV vaccine candidate, demonstrated high immunogenicity and a favorable safety profile in a Phase 1 trial for older adults....
3 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
